The vaccine, called Ad26.COV2.S, was equally well-tolerated at two different doses, the results showed. Based on the current results, J&J on Wednesday kicked off a final 60,000-person trial, which could pave the way for an application for regulatory approval. The company said it expects results of that so-called Phase 3 trial by the end of the year or early next year. However, immune response results were available from only a small number of people - 15 participants - over 65 years old, limiting the interpretation. Chan School of Public Health who was not involved in the J&J trial, told Reuters.

Source: bd News24 September 25, 2020 18:45 UTC